Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NXn3XJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7lTWM2OD1yLkC2NUDPxE1? MVzTRW5ITVJ?
ALL-PO NH7teIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjyTWM2OD1yLkC2N|U2KM7:TR?= MVrTRW5ITVJ?
697 M{nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnETWM2OD1yLkC5PVc3KM7:TR?= MmqxV2FPT0WU
NCI-H748 M4foPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXteXRKSzVyPUCuNVA{OzRizszN M3vpdHNCVkeHUh?=
NKM-1 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnwTWM2OD1yLkGwPVEzKM7:TR?= NG\RXVRUSU6JRWK=
ES1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMUGyOVUh|ryP Mlq3V2FPT0WU
NCI-H1963 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[yVZV2UUN3ME2wMlEyPTd7IN88US=> MV\TRW5ITVJ?
NCI-H1417 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMUK5O|Qh|ryP NYCwSZA{W0GQR1XS
NEC8 NEHsdo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3JTWM2OD1yLkGzOVI4KM7:TR?= MVLTRW5ITVJ?
CRO-AP2 M3rlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMU[4PFkh|ryP M4HPXXNCVkeHUh?=
A3-KAW NX3SWlNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\HNmlEPTB;MD6xO|YzPyEQvF2= M2C0XHNCVkeHUh?=
SF539 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\iUmlEPTB;MD6xPVU6OyEQvF2= NGHRVlVUSU6JRWK=
NOS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMUm2NVkh|ryP MnrmV2FPT0WU
NTERA-S-cl-D1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXGVlU4UUN3ME2wMlIxOTF|IN88US=> MljxV2FPT0WU
COR-L88 M3\pOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMkK5OVkh|ryP MnLWV2FPT0WU
EM-2 NVj5Z45oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;VTGM6UUN3ME2wMlI1ODd7IN88US=> M1:5NHNCVkeHUh?=
KARPAS-45 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4niT2lEPTB;MD6yO|g{OyEQvF2= NHjMTlVUSU6JRWK=
DSH1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PFNmlEPTB;MD6yPFcxQCEQvF2= MYXTRW5ITVJ?
HT-144 NWjXT4pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33zd2lEPTB;MD6zNFI2PiEQvF2= M{C3cXNCVkeHUh?=
ATN-1 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwM{C1O|Yh|ryP MmfOV2FPT0WU
HEL NEfrS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHjRXFKSzVyPUCuN|E{PDhizszN MYnTRW5ITVJ?
NB12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\S[FE5UUN3ME2wMlMyPzV4IN88US=> NWT3Wlg6W0GQR1XS
LU-139 M4fjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwM{O1NUDPxE1? M3nZWnNCVkeHUh?=
J-RT3-T3-5 NEPjclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PLNGlEPTB;MD6zN|cyPiEQvF2= NIjVW5lUSU6JRWK=
MOLT-13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfVV4JKSzVyPUCuN|M5OSEQvF2= Ml;YV2FPT0WU
SR NXLk[WhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHu[ZpOUUN3ME2wMlM1OjZzIN88US=> Ml7tV2FPT0WU
CMK NHnZfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIntOnlKSzVyPUCuN|U4OjdizszN MorNV2FPT0WU
ES8 NEfobY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTJTWM2OD1yLkO2NFIzKM7:TR?= MoW0V2FPT0WU
LB647-SCLC Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TtWmlEPTB;MD6zOlc{KM7:TR?= M4D3XHNCVkeHUh?=
TE-8 NYHtTI0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TqNWlEPTB;MD6zOlk{PSEQvF2= MWDTRW5ITVJ?
BV-173 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jM[WlEPTB;MD6zO|EzOSEQvF2= M1TSR3NCVkeHUh?=
DEL NVTmbm5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwM{e0PFch|ryP NGi0eWhUSU6JRWK=
ARH-77 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PCcGlEPTB;MD6zPFE6OyEQvF2= MX\TRW5ITVJ?
NCCIT Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHZTWM2OD1yLkO4OlQ6KM7:TR?= MlvpV2FPT0WU
RPMI-8402 NW\qR2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6RWhDUUN3ME2wMlM5PzBzIN88US=> M{T3OnNCVkeHUh?=
MONO-MAC-6 M1jVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwM{i3O|Yh|ryP NFnScIVUSU6JRWK=
SK-MM-2 NF:wd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTKeJdMUUN3ME2wMlM6QDZ6IN88US=> NHPmcZJUSU6JRWK=
CHP-126 NGqxZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWzZ2FKSzVyPUCuOFAzOzFizszN Mn;1V2FPT0WU
A101D Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnkTWM2OD1yLkSwN{DPxE1? NEXUemZUSU6JRWK=
SCH NHztSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwNECzOFIh|ryP M1zvb3NCVkeHUh?=
NMC-G1 M{\L[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\1PXVbUUN3ME2wMlQxOzZ5IN88US=> NWDPS2JQW0GQR1XS
NCI-H209 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nUcmlEPTB;MD60NFYyOyEQvF2= MXnTRW5ITVJ?
MOLT-16 NUTCS3gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i3UWlEPTB;MD60NVAyPyEQvF2= MUjTRW5ITVJ?
RPMI-6666 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK4OIV6UUN3ME2wMlQyOTJizszN MojXV2FPT0WU
OPM-2 NUjtepRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7yTWM2OD1yLkSxOVE{KM7:TR?= NXuzcFR4W0GQR1XS
MRK-nu-1 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHve49KSzVyPUCuOFMyPTNizszN NGjLR3pUSU6JRWK=
BC-1 NYfadZRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\uS2lEPTB;MD60N|QxOyEQvF2= NInGTHNUSU6JRWK=
MHH-NB-11 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwNEO0OVMh|ryP MWPTRW5ITVJ?
Ramos-2G6-4C10 NGK3RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDBNllVUUN3ME2wMlQ{QDl5IN88US=> Mmr2V2FPT0WU
LS-513 NWLvfVRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXBWYRYUUN3ME2wMlQ1PTBzIN88US=> NGfFdYxUSU6JRWK=
K5 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fiNGlEPTB;MD60O|AzPSEQvF2= NYDtdnl4W0GQR1XS
HOP-62 NXTx[nAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwNEizOVgh|ryP M2fy[XNCVkeHUh?=
NCI-H187 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmyV3pKSzVyPUCuOFkzOjdizszN NVrGUVE2W0GQR1XS
BE-13 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlTWM2OD1yLkS5OlYyKM7:TR?= M3;PVHNCVkeHUh?=
HC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HhSWlEPTB;MD61NFQ4OyEQvF2= M3G3OHNCVkeHUh?=
ACN MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f0bWlEPTB;MD61NVAzQCEQvF2= MXrTRW5ITVJ?
HCC1599 M1;ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS4TWM2OD1yLkWxOVch|ryP M4LqZ3NCVkeHUh?=
MV-4-11 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3yTWM2OD1yLkWzNFQyKM7:TR?= M1PnOXNCVkeHUh?=
LC-2-ad Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwNUO2OlMh|ryP M4\2fXNCVkeHUh?=
HL-60 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXSTWM2OD1yLkW0NlYyKM7:TR?= MUXTRW5ITVJ?
NB17 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwNUSzPEDPxE1? M2rufnNCVkeHUh?=
TE-1 NWnBc3VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXoTWM2OD1yLkW1N|A3KM7:TR?= MkeyV2FPT0WU
NCI-H524 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn60TWM2OD1yLkW1OFAyKM7:TR?= MWLTRW5ITVJ?
MZ7-mel M3\xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwNU[xNFUh|ryP NHTvd|lUSU6JRWK=
L-363 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTvTWM2OD1yLkW2OlU4KM7:TR?= Ml;wV2FPT0WU
BL-41 NYnvNGVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y2RWlEPTB;MD61Olg5QSEQvF2= Mn;vV2FPT0WU
LU-134-A NXrGeodsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXBfpRKSzVyPUCuOVcxPzNizszN M2TMe3NCVkeHUh?=
SIG-M5 MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfsWXNKSzVyPUCuOVc5PDhizszN MVzTRW5ITVJ?
ONS-76 M2C2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;0e2lEPTB;MD61PFI1OiEQvF2= Moi1V2FPT0WU
KARPAS-299 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPZcVJKSzVyPUCuOVg2ODRizszN NES2[FhUSU6JRWK=
DU-4475 M4C1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLNTWM2OD1yLkW4O|A{KM7:TR?= NIPFTXpUSU6JRWK=
NB69 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTsSldGUUN3ME2wMlU6QDJ3IN88US=> Mle0V2FPT0WU
MHH-PREB-1 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH6TWM2OD1yLk[wO|E6KM7:TR?= MkftV2FPT0WU
LU-165 NI\RcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC3TWM2OD1yLk[xPFEzKM7:TR?= MmjxV2FPT0WU
LOUCY MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLqd5ZKSzVyPUCuOlM{PjRizszN M1\BenNCVkeHUh?=
NCI-H526 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\jcmlEPTB;MD62N|U1OSEQvF2= MWnTRW5ITVJ?
KE-37 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnToTWM2OD1yLk[0Nlc3KM7:TR?= MmrhV2FPT0WU
NALM-6 M4C3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPtV|dKSzVyPUCuOlQ5PiEQvF2= NHzsc49USU6JRWK=
CW-2 M4\BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNkW3PVQh|ryP M2SwU3NCVkeHUh?=
SU-DHL-1 M1\sOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLiTWM2OD1yLk[1PVQ4KM7:TR?= MnLXV2FPT0WU
NB13 NYX3cmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrKV3VKSzVyPUCuOlY5OTdizszN NXW0cmZ5W0GQR1XS
QIMR-WIL MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTVTWM2OD1yLk[4N|Q{KM7:TR?= MlnCV2FPT0WU
ECC12 NXfUXo9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwN{CwPFYh|ryP NUHieXlkW0GQR1XS
KALS-1 NHT4TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrBbm9KSzVyPUCuO|A1QTJizszN MXrTRW5ITVJ?
COR-L279 M3H4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXVTWM2OD1yLkewPVk3KM7:TR?= NVjFTo1FW0GQR1XS
NB14 NWm0TpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nocWlEPTB;MD63NlYyPyEQvF2= NUS3WYpNW0GQR1XS
CCRF-CEM NHS4W5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[4c2lEPTB;MD63OFY3OSEQvF2= MnK5V2FPT0WU
SW954 M3\Zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrIRXNKSzVyPUCuO|U6QTlizszN NUPLcY1bW0GQR1XS
IST-SL1 NWrObmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTaTWM2OD1yLke3N|Q5KM7:TR?= NYPPdIN[W0GQR1XS
LAMA-84 NXG1VWdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwN{e1Olch|ryP M1vTWXNCVkeHUh?=
Daudi NWC0fJdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vYZWlEPTB;MD63O|Y5OSEQvF2= NV3ydXpbW0GQR1XS
BC-3 NGLz[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwN{izNFgh|ryP NY\ibml7W0GQR1XS
HCC2998 NVXG[3B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\U[WlEPTB;MD63PFM3KM7:TR?= NG\WR4hUSU6JRWK=
NCI-H69 NVG3UWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP3TWM2OD1yLkiwNVQ4KM7:TR?= NV33[GFPW0GQR1XS
CPC-N MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwOEC1NlQh|ryP M{fGUXNCVkeHUh?=
NOMO-1 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwOEGwPFQh|ryP NV74RlBkW0GQR1XS
CESS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorwTWM2OD1yLkixNVk4KM7:TR?= MWfTRW5ITVJ?
LC4-1 NH3NXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLzOo1yUUN3ME2wMlg1ODB5IN88US=> NYjMdYkyW0GQR1XS
BL-70 M1LWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDJb|FKSzVyPUCuPFU4ODJizszN NGnn[JBUSU6JRWK=
ES4 NE\We4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwOEW4Olgh|ryP MU\TRW5ITVJ?
HCE-T M13L[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13HR2lEPTB;MD64O|E4OSEQvF2= MV;TRW5ITVJ?
JAR M3z3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu4SHpSUUN3ME2wMlg4QDJ5IN88US=> NV3iWJFXW0GQR1XS
ST486 M{juWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwOEe5NVch|ryP M2njZnNCVkeHUh?=
KS-1 NYTVcpVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTNbYJuUUN3ME2wMlg5ODl4IN88US=> MUnTRW5ITVJ?
GDM-1 NEO4NlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTJemQ5UUN3ME2wMlg5Pjh5IN88US=> NGXoSZVUSU6JRWK=
EHEB NEOxU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwOUK1PFUh|ryP NFv6XFlUSU6JRWK=
LB2518-MEL MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfl[W1KSzVyPUCuPVMzQDRizszN MX7TRW5ITVJ?
GOTO MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwTWM2OD1yLkm1NFc3KM7:TR?= NHjJ[WJUSU6JRWK=
LXF-289 NF:wS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPySYRKSzVyPUCuPVU6ODFizszN MYHTRW5ITVJ?
ES6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\5TWM2OD1yLkm2OFM4KM7:TR?= MmHuV2FPT0WU
OS-RC-2 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHOTWM2OD1yLkm2PFMh|ryP MXTTRW5ITVJ?
DMS-153 M3XvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;mVWlEPTB;MD65O|Q3QSEQvF2= MXnTRW5ITVJ?
SK-PN-DW M3TyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrRcXhKSzVyPUCuPVc5OzFizszN NHfHb4NUSU6JRWK=
HH MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD1yLkm4PVU6KM7:TR?= MVnTRW5ITVJ?
SH-4 M4Pt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwMEK0NUDPxE1? NUjxR|dqW0GQR1XS
MOLT-4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G0O2lEPTB;MT6wN|Q2PCEQvF2= NED3T3BUSU6JRWK=
TGW NV\iTHZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPDTWM2OD1zLkC3Olc2KM7:TR?= M3XKd3NCVkeHUh?=
L-540 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwMUC2NFQh|ryP NGTYNpRUSU6JRWK=
PF-382 NGLKPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwMUG1NVMh|ryP NHzreGFUSU6JRWK=
LC-1F NEfvO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwMUKwNFch|ryP MmHkV2FPT0WU
OVCAR-4 NYe3UoxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwMUOxOlUh|ryP MljKV2FPT0WU
A4-Fuk Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDUZ5VKSzVyPUGuNVU{PjRizszN NXTaU2JVW0GQR1XS
HCC2218 NGnifIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXSTWM2OD1zLkG2OlQyKM7:TR?= NX\aWZJTW0GQR1XS
HAL-01 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrxTWM2OD1zLkG2PVQ{KM7:TR?= NX7MT2FLW0GQR1XS
IST-MEL1 NWjSTXJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\wWWlEPTB;MT6xO|Y2QSEQvF2= MXTTRW5ITVJ?
NCI-H719 M{LZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v3SGlEPTB;MT6xO|g6QCEQvF2= MnHiV2FPT0WU
EVSA-T MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwMUixNVQh|ryP MlvhV2FPT0WU
SK-NEP-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;XTWM2OD1zLkKwNlY3KM7:TR?= NVzOZWc1W0GQR1XS
OCUB-M MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj2OY5KSzVyPUGuNlE1QDlizszN NXG5XJJ1W0GQR1XS
MEG-01 NYfNOldET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qxXGlEPTB;MT6yNlEyQCEQvF2= NETNN5NUSU6JRWK=
no-10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMkOxNVIh|ryP MkC5V2FPT0WU
MHH-CALL-2 M3:wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Bd3ZJUUN3ME2xMlI1PzJzIN88US=> M2fuZ3NCVkeHUh?=
SK-N-DZ NWWwU2F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fXbWlEPTB;MT6yOFc4PiEQvF2= MWTTRW5ITVJ?
SCLC-21H MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvZ[W1SUUN3ME2xMlI3PDd6IN88US=> NYjIZm9lW0GQR1XS
CTV-1 NFr2UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwMke0NlUh|ryP MXvTRW5ITVJ?
NB1 NUH2bHZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\yfGtvUUN3ME2xMlI4PzN{IN88US=> NIHTVWtUSU6JRWK=
NCI-H64 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwMki0OlIh|ryP MoGwV2FPT0WU
MDA-MB-134-VI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwMki1O|ch|ryP NEW3TGlUSU6JRWK=
LB2241-RCC MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTLW3BkUUN3ME2xMlI5PjZ|IN88US=> NXLuOYxpW0GQR1XS
8-MG-BA Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLvTWM2OD1zLkK4PFY3KM7:TR?= M3rL[HNCVkeHUh?=
LP-1 M3H5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rSO2lEPTB;MT6yPVk1PyEQvF2= NFrENGlUSU6JRWK=
LS-411N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OzbmlEPTB;MT6zNFk6QCEQvF2= NFjzV|JUSU6JRWK=
CAL-148 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fKcmlEPTB;MT6zNlU1OiEQvF2= MVzTRW5ITVJ?
NCI-H2171 NEXISVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\icIFKSzVyPUGuN|Q2ODJizszN NFXGdVRUSU6JRWK=
JiyoyeP-2003 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK1TmFKSzVyPUGuN|U{QSEQvF2= NEHpRXFUSU6JRWK=
NCI-H2107 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mwcmlEPTB;MT6zOVg5OyEQvF2= MUnTRW5ITVJ?
BB30-HNC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO5TWM2OD1zLkO4PVc5KM7:TR?= MoXXV2FPT0WU
K-562 NEfaS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\lTWM2OD1zLkO5NlE6KM7:TR?= MVrTRW5ITVJ?
PSN1 M{SzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fpd2lEPTB;MT60NlI5PyEQvF2= Mne0V2FPT0WU
HCC2157 M2P2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonqTWM2OD1zLkSyOlkyKM7:TR?= M2PqfHNCVkeHUh?=
SBC-1 M1HNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwNEK3OFEh|ryP NIPUPJVUSU6JRWK=
MC116 NV;jUpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrDb5pKSzVyPUGuOFM3OTVizszN M4LGSHNCVkeHUh?=
KARPAS-422 NFTqOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDGTWM2OD1zLkS1N|U5KM7:TR?= MV;TRW5ITVJ?
LB996-RCC MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr2RXJjUUN3ME2xMlQ4OTB|IN88US=> MmLYV2FPT0WU
MSTO-211H MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\zZ49KSzVyPUGuOFc6QDdizszN NX;FSHN3W0GQR1XS
BT-474 M{LKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHJTWM2OD1zLkWxO|Y1KM7:TR?= M33oTnNCVkeHUh?=
A388 M3vYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfzd2lKSzVyPUGuOVE6PDVizszN M{G2cnNCVkeHUh?=
SJSA-1 M4DSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTDTWM2OD1zLkWyNlYh|ryP NIOydFdUSU6JRWK=
COLO-829 M3[xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvtV|Z7UUN3ME2xMlU{PTZ2IN88US=> NVHaV|VzW0GQR1XS
KM-H2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwNU[2O{DPxE1? MkLTV2FPT0WU
GR-ST M2fSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwNU[4NkDPxE1? MVTTRW5ITVJ?
RPMI-8866 NGfQT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\MTWM2OD1zLk[wNVQ1KM7:TR?= NHLaXItUSU6JRWK=
KG-1 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT4N45MUUN3ME2xMlYyQTBzIN88US=> MXjTRW5ITVJ?
NCI-H82 NF:4[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrlbGdKSzVyPUGuOlM1ODZizszN M3PROXNCVkeHUh?=
LB1047-RCC NH7TT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwNkO0OVkh|ryP NWKzdWJjW0GQR1XS
KM12 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG1NoZKUUN3ME2xMlY1PyEQvF2= NUPhSmN5W0GQR1XS
NB5 NUHtcotsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvYTWM2OD1zLk[1Olc4KM7:TR?= NXfIZY5DW0GQR1XS
HDLM-2 NF\ydYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwNkiyPFEh|ryP NVftTXhWW0GQR1XS
KU812 NGfITWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID2OJlKSzVyPUGuOlk3ODVizszN MXnTRW5ITVJ?
DB MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXSTWM2OD1zLkewN|U{KM7:TR?= MYrTRW5ITVJ?
HD-MY-Z NWO2cJZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrKSW9KSzVyPUGuO|UzOzRizszN NGPDNI1USU6JRWK=
KURAMOCHI NU\Z[25ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwN{eyNFch|ryP MoHoV2FPT0WU
ETK-1 NVXydIY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nQ[GlEPTB;MT63PFg4QSEQvF2= MWHTRW5ITVJ?
SK-UT-1 M4LlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Jd2R3UUN3ME2xMlc6Ozh6IN88US=> NIXjcZFUSU6JRWK=
HUTU-80 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwN{m1NFgh|ryP MVLTRW5ITVJ?
ES7 NHLQeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwOECzNFIh|ryP NFP6NHNUSU6JRWK=
SW872 NHu4PGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TlbGlEPTB;MT64NVM6PSEQvF2= NGn3NJlUSU6JRWK=
TK10 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mzemlEPTB;MT64N|ExQCEQvF2= MUPTRW5ITVJ?
LB831-BLC NYDVO4FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fqZWlEPTB;MT64N|U3OyEQvF2= NGjPUFhUSU6JRWK=
TE-9 M{iyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL2TWM2OD1zLki0OFIzKM7:TR?= MlT5V2FPT0WU
MLMA NHXFN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P6RWlEPTB;MT64PFI{PCEQvF2= NGTLfolUSU6JRWK=
D-542MG MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwOEmzO|Mh|ryP MYTTRW5ITVJ?
EW-16 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojXTWM2OD1zLkmyO|Ih|ryP M{T5T3NCVkeHUh?=
LOXIMVI MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;WTWM2OD1zLkmzNlgh|ryP NWjafVJTW0GQR1XS
GB-1 NEnPe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn5UGZKSzVyPUGuPVM5PjZizszN NIHEcmhUSU6JRWK=
IST-SL2 NFPhS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonwTWM2OD1{LkCwNlYzKM7:TR?= M{\TfHNCVkeHUh?=
LAN-6 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLGTWM2OD1{LkCxPVY3KM7:TR?= M3LBc3NCVkeHUh?=
NCI-H510A NIrIZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX5fIpXUUN3ME2yMlA1PTB{IN88US=> MnroV2FPT0WU
NCI-H1092 NE\FVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjweWpKSzVyPUKuNFUyOjRizszN MmC5V2FPT0WU
HT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID6NpNKSzVyPUKuNVA1PTRizszN M4XhOHNCVkeHUh?=
RL95-2 M2ftRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XZNWlEPTB;Mj6xNVQ5OiEQvF2= M13rUXNCVkeHUh?=
NCI-H1355 NXfBXZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fvemlEPTB;Mj6xNVc6OiEQvF2= MWPTRW5ITVJ?
NCI-H720 NWi4OYlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwMU[4O|Mh|ryP NIr3V3ZUSU6JRWK=
NCI-H1522 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;iXYdKSzVyPUKuNlE4OjNizszN MUTTRW5ITVJ?
LB373-MEL-D M3qzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XzfGlEPTB;Mj6yOlkxOiEQvF2= MWnTRW5ITVJ?
DG-75 NXTVUXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwMkexOFgh|ryP M{\wfHNCVkeHUh?=
ML-2 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TRXGlEPTB;Mj6zNlg2PSEQvF2= MVLTRW5ITVJ?
SF126 NX7JfJl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz2cXZsUUN3ME2yMlM{ODl2IN88US=> M17r[3NCVkeHUh?=
MPP-89 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz5XGlKSzVyPUKuN|MyPDVizszN MkTVV2FPT0WU
NCI-H345 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPtRWNKSzVyPUKuN|MzPzdizszN MnuxV2FPT0WU
LS-123 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P6NWlEPTB;Mj6zOFk{PiEQvF2= NXS5cXNbW0GQR1XS
NB10 M373PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnEWI9mUUN3ME2yMlQyODl{IN88US=> MVvTRW5ITVJ?
CGTH-W-1 M37PSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJwNEKyOlch|ryP M2HFV3NCVkeHUh?=
CP66-MEL M1q2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwNEe3O{DPxE1? NU\K[WFCW0GQR1XS
L-428 NULXNppsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj2SHFKSzVyPUKuOFg2OjFizszN MljKV2FPT0WU
DMS-79 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLLNFNqUUN3ME2yMlU1OTB|IN88US=> MVrTRW5ITVJ?
NCI-H1882 NF3PVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoixTWM2OD1{Lk[3OVYzKM7:TR?= MoXKV2FPT0WU
KGN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH4RWhKSzVyPUKuO|Y5PzZizszN MV;TRW5ITVJ?
EW-1 M{HJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvIO3lUUUN3ME2yMlc4ODh|IN88US=> NFrnTIJUSU6JRWK=
U-266 NGLFN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;0VVdnUUN3ME2yMlg1QDJ|IN88US=> MoLNV2FPT0WU
COLO-320-HSR NYL6RVJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJwOEW2OFEh|ryP MnjOV2FPT0WU
KMOE-2 NFL1UZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3OGlEPTB;Mj64O|cyOSEQvF2= M1vaTXNCVkeHUh?=
BB49-HNC Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\YRmlEPTB;Mj65NlQ5KM7:TR?= NGLEd3NUSU6JRWK=
GI-1 NXTqU3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwOUK5OVch|ryP MX3TRW5ITVJ?
NCI-H1304 M4D2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[3TWM2OD1|LkCwOVEyKM7:TR?= MVjTRW5ITVJ?
NCI-H2227 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXXVYVtUUN3ME2zMlAzODd7IN88US=> MnTSV2FPT0WU
U-87-MG M1XlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rlTmlEPTB;Mz6wN|UyOyEQvF2= MlruV2FPT0WU
NCI-H747 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\XWGlEPTB;Mz6wOVIxPiEQvF2= NES5V5JUSU6JRWK=
CTB-1 NHjqTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwMEWzO|Yh|ryP NFm2UZRUSU6JRWK=
RPMI-8226 NHLGVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\rSGlEPTB;Mz6xOFM4QCEQvF2= M4Kyd3NCVkeHUh?=
NCI-H2141 M{nrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTNwMU[1OlYh|ryP MVnTRW5ITVJ?
IST-MES1 NHzLTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn1W5RXUUN3ME2zMlE5Ojd7IN88US=> MULTRW5ITVJ?
TE-5 M1nVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Cd2RKSzVyPUOuNlE{PDJizszN M2rtVHNCVkeHUh?=
UACC-257 NYT5U2dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHznWIpKSzVyPUOuOFM3PTlizszN MnewV2FPT0WU
SK-N-FI MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;Nb3hKSzVyPUOuOFUzOjdizszN MljVV2FPT0WU
MFH-ino MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwNE[1PFkh|ryP M37WfnNCVkeHUh?=
SF268 NVK0[5B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17n[mlEPTB;Mz60PFE4PCEQvF2= MXzTRW5ITVJ?
TE-12 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ixcGlEPTB;Mz61NVY6QSEQvF2= NYHUSnk4W0GQR1XS
NB6 M2rOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPEc2JrUUN3ME2zMlU2PTZ|IN88US=> M4\Mc3NCVkeHUh?=
DJM-1 NIPyboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwNUm4PVkh|ryP NGPTelZUSU6JRWK=
MZ1-PC NYLoSnhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XLRWlEPTB;Mz62NVYzPCEQvF2= M3TmbnNCVkeHUh?=
OCI-AML2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvSUZQ{UUN3ME2zMlYzPjdzIN88US=> NWHHXZV[W0GQR1XS
NCI-H1155 M{XtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfCdVhKSzVyPUOuO|A6PDdizszN MVTTRW5ITVJ?
RKO M1vU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXEUY9KSzVyPUOuO|cyQDlizszN MorYV2FPT0WU
ECC4 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfLbIFKSzVyPUOuPVcyQTVizszN MYXTRW5ITVJ?
BB65-RCC NXrEVmZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjETWM2OD1|Lkm3OVQ4KM7:TR?= MlfJV2FPT0WU
EB-3 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HM[2lEPTB;Mz65PVY{OyEQvF2= M1f0WXNCVkeHUh?=
SHP-77 M{P5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jwdWlEPTB;ND6wNFUzPCEQvF2= MXjTRW5ITVJ?
NCI-H2196 NV7YWIVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne1TWM2OD12LkC1OlI2KM7:TR?= M2[1VnNCVkeHUh?=
GI-ME-N MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzOTWM2OD12LkC2N|k6KM7:TR?= MUTTRW5ITVJ?
MN-60 MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXflV3J[UUN3ME20MlExQDdizszN MoWyV2FPT0WU
NCI-H1694 NUCyeFZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRwMUO0NFUh|ryP M3XUU3NCVkeHUh?=
LU-65 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7XO4RMUUN3ME20MlE2OzN{IN88US=> NUHOWWVrW0GQR1XS
NCI-H1436 NF\IXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojpTWM2OD12LkG4N|M{KM7:TR?= M2f2UHNCVkeHUh?=
KINGS-1 NUCyWo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwM{G0N|Ih|ryP M1W2VXNCVkeHUh?=
GT3TKB M37uZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwM{OyOlgh|ryP NGm5V29USU6JRWK=
Becker MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\EfIJKSzVyPUSuN|c{OTJizszN MlzoV2FPT0WU
HCC1187 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT2TWM2OD12Lki5OlU4KM7:TR?= MYTTRW5ITVJ?
D-502MG NFHrVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXJTWM2OD13LkCwOFE3KM7:TR?= NHq2PY9USU6JRWK=
VA-ES-BJ NXnwSJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTVwMUO3O|gh|ryP MXXTRW5ITVJ?
NB7 NYTue2tZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTBTWM2OD13LkG0NVEzKM7:TR?= M3PtSXNCVkeHUh?=
SW962 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\peolKSzVyPUWuN|g5OTRizszN M2HSNXNCVkeHUh?=
no-11 MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT0cFJLUUN3ME21Mlc3OzR|IN88US=> NVHLXFRpW0GQR1XS
KNS-81-FD NH3GVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:4TmFIUUN3ME21MlkxPjl2IN88US=> MVXTRW5ITVJ?
COLO-684 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW4R|ZQUUN3ME21Mlk6PDl2IN88US=> MlTPV2FPT0WU
D-263MG NELUfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTZwMEi4PVUh|ryP NF:2ZZJUSU6JRWK=
EW-24 M4\LfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknlTWM2OD14LkK4OVEh|ryP MY\TRW5ITVJ?
TE-10 NYS4eVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTZwNEK2NlMh|ryP MkH2V2FPT0WU
EKVX MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VTVdKSzVyPU[uOFY{OjFizszN Mo\hV2FPT0WU
NCI-H1648 NYH4TYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZwNke1OVch|ryP MmC3V2FPT0WU
LB771-HNC M{H5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M322XGlEPTB;Nj65NlMxOSEQvF2= M4\qOHNCVkeHUh?=
SK-MEL-1 NXrsSIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPKTWM2OD16LkGzNVY3KM7:TR?= MmfuV2FPT0WU
COLO-668 NEnZNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRThwMke3PFYh|ryP NHvRdIxUSU6JRWK=
EW-12 M1PiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn3c5N1UUN3ME24MlQxQDB|IN88US=> M3vEVHNCVkeHUh?=
A253 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHlT4NKSzVyPUiuPFQ3PjFizszN NYTQdHBXW0GQR1XS
NCI-H2126 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRThwOEmzNVkh|ryP NVvtUpkzW0GQR1XS
Calu-6 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi4XZVKSzVyPUiuPVkxPDJizszN NXnXSHlIW0GQR1XS
NCI-H23 NIDPcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTlwMUe3OFYh|ryP NGL0To9USU6JRWK=
WSU-NHL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rUb2lEPTB;OT63O|Q4QCEQvF2= Mo\PV2FPT0WU
MMAC-SF NXfTN4dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPGTWM2OD17Lkm3PVA1KM7:TR?= NV[0UIRNW0GQR1XS
SK-LMS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;WW5R1UUN3ME2xNE4zQDN2IN88US=> M2DEbnNCVkeHUh?=
GCIY MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHCTWM2OD1zMD61PVI1KM7:TR?= NUSxN|RlW0GQR1XS
TE-15 NEDQNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr6cXdKSzVyPUGxMlYxODRizszN M2DiTnNCVkeHUh?=
EoL-1-cell NVHjTIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\5bFVKSzVyPUGxMlc3QDJizszN MmjvV2FPT0WU
NCI-H2081 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLITWM2OD1zMT63O|g3KM7:TR?= NYrYcFJ{W0GQR1XS
EW-3 NHHodlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDjU2ZKSzVyPUGyMlI1PjNizszN MWDTRW5ITVJ?
CAS-1 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDldoJNUUN3ME2xNk4{PjNzIN88US=> NXy5WldMW0GQR1XS
C2BBe1 M{HucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C0XmlEPTB;MUKuOlE{OSEQvF2= NGPx[4xUSU6JRWK=
D-247MG NX64O3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF{Lke5OVIh|ryP MXPTRW5ITVJ?
NCI-SNU-5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\NTWM2OD1zMj64NFE{KM7:TR?= M1:1R3NCVkeHUh?=
LS-1034 NGXKdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF2LkO5O|Uh|ryP NE\TbJlUSU6JRWK=
EW-18 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS2PWdKSzVyPUG0MlQ1QCEQvF2= MWDTRW5ITVJ?
Raji NYO0NGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Die2lEPTB;MUSuOVA1QSEQvF2= NXPYbXM4W0GQR1XS
D-283MED NELpbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF2Lk[yO|Eh|ryP MX;TRW5ITVJ?
MZ2-MEL M{nOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF2Lkm2PVYh|ryP MmfaV2FPT0WU
NCI-SNU-16 NYnSXXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe2V4hKSzVyPUG1MlQ3OzNizszN NF\nTlFUSU6JRWK=
P30-OHK NFHlTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv5bZpKSzVyPUG3Mlc5OzFizszN MXvTRW5ITVJ?
RXF393 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\rRmlEPTB;MUmuNFE5PiEQvF2= MYHTRW5ITVJ?
NCI-H1395 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULh[G1tUUN3ME2yNE43PzB|IN88US=> MoPPV2FPT0WU
U-698-M NYXNdW1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHHTWM2OD1{MD63NFc2KM7:TR?= MnfrV2FPT0WU
NCI-SNU-1 M17NcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJyLkeyNlMh|ryP M3LifnNCVkeHUh?=
SW684 M124SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTNfYV4UUN3ME2yNU4yPzF4IN88US=> NInJUGlUSU6JRWK=
NCI-H716 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJzLkOxOVQh|ryP NYrIUlVtW0GQR1XS
JVM-2 NXrHPHl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3UmlEPTB;MkGuOFE{OyEQvF2= NE\VSYtUSU6JRWK=
NCI-H1581 M1nLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLDVVNKSzVyPUKyMlQyPDhizszN MlLPV2FPT0WU
CA46 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7PV3V4UUN3ME2zNU43QTN4IN88US=> MmO5V2FPT0WU
SNB75 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Lv[WlEPTB;M{OuOlUxOyEQvF2= NUjvW2h7W0GQR1XS
KNS-42 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rTWM2OD1|NT65OlI1KM7:TR?= M4nSRXNCVkeHUh?=
TUR MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN4LkC1NlEh|ryP MoTkV2FPT0WU
REH MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX6TVZTUUN3ME2zO{45OjFzIN88US=> MWLTRW5ITVJ?
EW-22 NVPhb2s3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i0T2lEPTB;NEKuNlg5PSEQvF2= M2fGTHNCVkeHUh?=
NCI-H446 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvDTWM2OD12Mj63PFU{KM7:TR?= NYPPc24yW0GQR1XS
ES3 NWrDbnJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjKTWM2OD12Mz6xN|M6KM7:TR?= MlLuV2FPT0WU
EW-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTR2LkiyNVgh|ryP NYnabXd6W0GQR1XS
RH-1 M{HqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITISXFKSzVyPUS3MlU5OTJizszN NIK5e21USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals December 15 2018 Phase 1
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network August 31 2018 Phase 2
NCT03538171 Recruiting Advanced Breast Cancer EddingPharm Oncology Co. LTD. May 15 2018 Phase 3
NCT03501381 Recruiting Renal Cell Carcinoma Roberto Pili|Indiana University Melvin and Bren Simon Cancer Center|Prometheus Laboratories|Syndax Pharmaceuticals|Hoosier Cancer Research Network May 24 2018 Phase 2
NCT02697630 Recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals February 21 2018 Phase 2
NCT03361800 Recruiting Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) January 22 2018 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID